Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Jun 28

PMID 34177949

Citations 10

Authors

Sigridur Sunna Aradottir

Ann-Charlotte Kristoffersson

Lubka T Roumenina

Anna Bjerre

Pavlos Kashioulis

Runolfur Palsson

Diana Karpman

Affiliations

Soon will be listed here.

Abstract

Complement factor B (FB) mutant variants are associated with excessive complement activation in kidney diseases such as atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy and membranoproliferative glomerulonephritis (MPGN). Patients with aHUS are currently treated with eculizumab while there is no specific treatment for other complement-mediated renal diseases. In this study the phenotype of three FB missense variants, detected in patients with aHUS (D371G and E601K) and MPGN (I242L), was investigated. Patient sera with the D371G and I242L mutations induced hemolysis of sheep erythrocytes. Mutagenesis was performed to study the effect of factor D (FD) inhibition on C3 convertase-induced FB cleavage, complement-mediated hemolysis, and the release of soluble C5b-9 from glomerular endothelial cells. The FD inhibitor danicopan abrogated C3 convertase-associated FB cleavage to the Bb fragment in patient serum, and of the FB constructs, D371G, E601K, I242L, the gain-of-function mutation D279G, and the wild-type construct, in FB-depleted serum. Furthermore, the FD-inhibitor blocked hemolysis induced by the D371G and D279G gain-of-function mutants. In FB-depleted serum the D371G and D279G mutants induced release of C5b-9 from glomerular endothelial cells that was reduced by the FD-inhibitor. These results suggest that FD inhibition can effectively block complement overactivation induced by FB gain-of-function mutations.

Citing Articles

Factor B as a therapeutic target for the treatment of complement-mediated diseases.

Kavanagh D, Barratt J, Schubart A, Webb N, Meier M, Fakhouri F Front Immunol. 2025; 16:1537974.

PMID: 40028332 PMC: 11868072. DOI: 10.3389/fimmu.2025.1537974.

C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation.

Heidenreich K, Goel D, Priyamvada P, Kulkarni S, Chakurkar V, Khullar D Front Nephrol. 2024; 4:1460146.

PMID: 39534179 PMC: 11554616. DOI: 10.3389/fneph.2024.1460146.

Complement dysregulation associated with a genetic variant in factor H-related protein 5 in atypical hemolytic uremic syndrome.

Aradottir S, Kristoffersson A, Linner E, Karpman D Pediatr Nephrol. 2023; 39(4):1105-1111.

PMID: 37955705 PMC: 10899364. DOI: 10.1007/s00467-023-06184-6.

Clinical advances in immunotherapy for immune-mediated glomerular diseases.

Tang B, Yang X Clin Exp Med. 2023; 23(8):4091-4105.

PMID: 37889398 PMC: 10725396. DOI: 10.1007/s10238-023-01218-7.

Genetic investigation of Nordic patients with complement-mediated kidney diseases.

Rydberg V, Aradottir S, Kristoffersson A, Svitacheva N, Karpman D Front Immunol. 2023; 14:1254759.

PMID: 37744338 PMC: 10513385. DOI: 10.3389/fimmu.2023.1254759.

References

Phillips E, Westwood J, Brocklebank V, Wong E, Tellez J, Marchbank K . The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost. 2015; 14(1):175-85. PMC: 4737436. DOI: 10.1111/jth.13189. View

Marinozzi M, Roumenina L, Chauvet S, Hertig A, Bertrand D, Olagne J . Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. J Am Soc Nephrol. 2017; 28(5):1603-1613. PMC: 5407719. DOI: 10.1681/ASN.2016030343. View

Roumenina L, Jablonski M, Hue C, Blouin J, Dimitrov J, Dragon-Durey M . Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood. 2009; 114(13):2837-45. DOI: 10.1182/blood-2009-01-197640. View

Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S . Complement Activation and Thrombotic Microangiopathies. Clin J Am Soc Nephrol. 2019; 14(12):1719-1732. PMC: 6895490. DOI: 10.2215/CJN.05830519. View

Karpman D, Loos S, Tati R, Arvidsson I . Haemolytic uraemic syndrome. J Intern Med. 2016; 281(2):123-148. DOI: 10.1111/joim.12546. View

Karpman D, Hoglund P . Orphan drug policies and use in pediatric nephrology. Pediatr Nephrol. 2016; 32(1):1-6. DOI: 10.1007/s00467-016-3520-4. View

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E . Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016; 71:131-142. DOI: 10.1016/j.molimm.2016.01.010. View

Stahl A, Vaziri-Sani F, Heinen S, Kristoffersson A, Gydell K, Raafat R . Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood. 2008; 111(11):5307-15. DOI: 10.1182/blood-2007-08-106153. View

Rother U . A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods. 1982; 51(1):101-7. DOI: 10.1016/0022-1759(82)90386-6. View

10.

Roumenina L, Chadebech P, Bodivit G, Vieira-Martins P, Grunenwald A, Boudhabhay I . Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol. 2020; 95(5):456-464. DOI: 10.1002/ajh.25742. View

11.

Bekassy Z, Kristoffersson A, Cronqvist M, Roumenina L, Rybkine T, Vergoz L . Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrol Dial Transplant. 2013; 28(11):2899-907. DOI: 10.1093/ndt/gft340. View

12.

Hourcade D, Mitchell L, Oglesby T . Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding. J Immunol. 1999; 162(5):2906-11. View

13.

Maga T, Nishimura C, Weaver A, Frees K, Smith R . Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 2010; 31(6):E1445-60. DOI: 10.1002/humu.21256. View

14.

Alfakeeh K, Azar M, Alfadhel M, Abdullah A, AlOudah N, Alsaad K . Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab. Pediatr Nephrol. 2017; 32(5):885-891. DOI: 10.1007/s00467-016-3577-0. View

15.

Hourcade D, Mitchell L . Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein. J Biol Chem. 2011; 286(41):35725-35732. PMC: 3195642. DOI: 10.1074/jbc.M111.263418. View

16.

Milder F, Gomes L, Schouten A, Janssen B, Huizinga E, Romijn R . Factor B structure provides insights into activation of the central protease of the complement system. Nat Struct Mol Biol. 2007; 14(3):224-8. DOI: 10.1038/nsmb1210. View

17.

Merle N, Grunenwald A, Rajaratnam H, Gnemmi V, Frimat M, Figueres M . Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight. 2018; 3(12). PMC: 6124427. DOI: 10.1172/jci.insight.96910. View

18.

Slade C, Bosco J, Unglik G, Bleasel K, Nagel M, Winship I . Deficiency in complement factor B. N Engl J Med. 2013; 369(17):1667-9. DOI: 10.1056/NEJMc1306326. View

19.

Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang W, le Quintrec M . Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45(5):531-6. PMC: 3719402. DOI: 10.1038/ng.2590. View

20.

Maibaum J, Liao S, Vulpetti A, Ostermann N, Randl S, Rudisser S . Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat Chem Biol. 2016; 12(12):1105-1110. DOI: 10.1038/nchembio.2208. View